SEARCH

SEARCH BY CITATION

References

  • Arain, T.M., Resconi, A.E., Hickey, M.J. & Stover, C.K. (1996) Bioluminescence screening in vitro (Bio-Siv) assays for high-volume antimycobacterial drug discovery. Antimicrob Agents Chemother 40: 15361541.
  • Banerjee, A., Dubnau, E., Quemard, A., Balasubramanian, V., Um, K.S. & Wilson, T., et al. (1994) inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 263: 227230.
  • Barry, C.E., 3rd, Lee, R.E., Mdluli, K., Sampson, A.E., Schroeder, B.G., Slayden, R.A. & Yuan, Y. (1998) Mycolic acids: structure, biosynthesis and physiological functions. Prog Lipid Res 37: 143179.
  • Bass, J.B., Jr, Farer, L.S., Hopewell, P.C., O'Brien, R., Jacobs, R.F. & Ruben, F., et al. (1994) Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention. Am J Respir Crit Care Med 149: 13591374.
  • Cole, S.T., Brosch, R., Parkhill, J., Garnier, T., Churcher, C. & Harris, D., et al. (1998) Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393: 537544.
  • Cronan, J.E., Jr & Rock, C.O. (1996) Biosynthesis of Membrane lipids. In Escherichia coli and Salmonella: Cellular and Molecular Biology. Neidhardt, F.C. (ed.). Washington, DC: American Society for Microbiology Press, pp. 612636.
  • De Voss, J.J., Rutter, K., Schroeder, B.G., Su, H., Zhu, Y. & Barry, C.E., 3rd (2000) The salicylate-derived mycobactin siderophores of mycobacterium tuberculosis are essential for growth in macrophages. Proc Natl Acad Sci USA 97: 12521257.
  • Deretic, V., Philipp, W., Dhandayuthapani, S., Mudd, M.H., Curcic, R. & Garbe, T., et al. (1995) Mycobacterium tuberculosis is a natural mutant with an inactivated oxidative-stress regulatory gene: implications for sensitivity to isoniazid. Mol Microbiol 17: 889900.
  • Deretic, V., Pagan-Ramos, E., Zhang, Y., Dhandayuthapani, S. & Via, L.E. (1996) The extreme sensitivity of Mycobacterium tuberculosis to the front-line antituberculosis drug isoniazid. Nature Biotechnol 14: 15571561.
  • Dessen, A., Quenmard, A., Blanchard, J.S., Jacobs, W.R., Jr & Sacchettini, J.C. (1995) Crystal structure and function of the isoniazid target of Mycobacterium tuberculosis. Science 267: 16381641.
  • Dolin, P.J., Raviglione, M.C. & Kochi, A. (1994) Global tuberculosis incidence and mortality during 1990–2000. Bull WHO 72: 213220.
  • George, K.M., Yuan, Y., Sherman, D.R. & Barry, C.E., 3rd (1995) The biosynthesis of cyclopropanated mycolic acids in Mycobacterium tuberculosis: identification and functional analysis of CMAS-2. J Biol Chem 270: 2729227298.
  • Heym, B., Honore, N., Truffot-Pernot, C., Banerjee, A., Schurra, C. & Jacobs, W.R., Jr, et al. (1994) Implications of multidrug resistance for the future of short-course chemotherapy of tuberculosis: a molecular study. Lancet 344: 293298.
  • Jackowski, S., Murphy, C.M., Cronan, J.E., Jr, & Rock, C.O. (1989) Acetoacetyl-acyl carrier protein synthase. A target for the antibiotic thiolactomycin. J Biol Chem 264: 76247629.
  • Kapur, V., Li, L.-L., Hamrick, M.R., Plikaytis, B.B., Shinnick, T.M. & Telenti, A., et al. (1995) Rapid Mycobacterium species assignment and unambiguous identification of mutations associated with antimicrobial resistance in Mycobacterium tuberculosis by automated DNA sequencing. Arch Pathol Lab Med 119: 131138.
  • Kremer, L., Douglas, J.D., Baulard, A.R., Morehouse, C., Guy, M.R. & Alland, D., et al. (2000) Thiolactomycin and related-analogues as novel anti-mycobacterial agents targeting KasA and KasB condensing enzymes in Mycobacterium tuberculosis. J Biol Chem 275: 1685716864.
  • Lee, A.S., Lim, I.H., Tang, L.L., Telenti, A. & Wong, S.-Y. (1999) Contribution of kasA analysis to detection of isoniazid-resistant Mycobacterium tuberculosis in Singapore. Antimicrob Agents Chemother 43: 20872089.
  • Levy, C.W., Roujeinikova, A., Sedelnikova, S., Baker, P.J., Stuitje, A.R. & Slabas, A.R., et al. (1999) Molecular basis of triclosan activity. Nature 398: 383384.
  • Liu, J. & Nikaido, H. (1999) A mutant of Mycobacterium smegmatis defective in the biosynthesis of mycolic acids accumulates meromycolates. Proc Natl Acad Sci USA 96: 40114016.
  • McMurry, L.M., Oethinger, M. & Levy, S.B. (1998) Triclosan targets lipid synthesis (letter). Nature 394: 531532.
  • McMurry, L.M., McDermott, P.F. & Levy, S.B. (1999) Genetic evidence that InhA of Mycobacterium smegmatis is a target for triclosan. Antimicrob Agents Chemother 43: 711713.
  • Marrakchi, H., Laneelle, G. & Quemard, A. (2000) InhA, a target of the antituberculous drug isoniazid, is involved in a mycobacterial fatty acid elongation system, FAS-II. Microbiology 146: 289296.
  • Mdluli, K., Sherman, D.R., Hickey, M.J., Kreiswirth, B.N., Morris, S., Stover, C.K. & Barry, C.E., 3rd (1996) Biochemical and genetic data suggest that InhA is not the primary target for activated isoniazid in Mycobacterium tuberculosis. J Infect Dis 174: 10851090.
  • Mdluli, K., Slayden, R.A., Zhu, Y., Ramaswamy, S., Pan, X. & Mead, D., et al. (1998a) Inhibition of a Mycobacterium tuberculosis beta-ketoacyl ACP synthase by isoniazid. Science 280: 16071610.
  • Mdluli, K., Swanson, J., Fischer, E., Lee, R.E. & Barry, C.E., 3rd (1998b) Mechanisms involved in the intrinsic isoniazid resistance of Mycobacterium avium. Mol Microbiol 27: 12231233.
  • Musser, J.M., Kapur, V., Williams, D.L., Kreiswirth, B.N., Van Soolingen, D. & Van Embden, J.D. (1996) Characterization of the catalase-peroxidase gene (katG) and inhA locus in isoniazid-resistant and -susceptible strains of Mycobacterium tuberculosis by automated DNA sequencing: restricted array of mutations associated with drug resistance. J Infect Dis 173: 196202.
  • Nishida, I., Kawaguchi, A. & Yamada, M. (1986) Effect of thiolactomycin on the individual enzymes of the fatty acid synthase system in Escherichia coli. J Biochem (Tokyo) 99: 14471454.
  • Parikh, S.L., Xiao, G. & Tonge, P.J. (2000) Inhibition of InhA, the enoyl reductase from mycobacterium tuberculosis, by triclosan and isoniazid. Biochemistry 39: 76457650.
  • Piatek, A.S., Telenti, A., Murray, M.R., El-Hajj, H., Jacobs, W.R., Jr, Kramer, F.R. & Alland, D. (2000) Genotypic analysis of Mycobacterium tuberculosis in two distinct populations using molecular beacons: implications for rapid susceptibility testing. Antimicrob Agents Chemother 44: 103110.
  • Rouse, D.A., Li, Z., Bai, G.-H. & Morris, S.L. (1995) Characterization of the katG and inhA genes of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 39: 24722477.
  • Rozwarski, D.A., Grant, G.A., Barton, D.H.R., Jacobs, W.R., Jr & Sacchettini, J.C. (1998) Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. Science 279: 98102.
  • Sherman, D.R., Sabo, P.J., Hickey, M.J., Arain, T.M., Mahairas, G.G. & Yuan, Y., et al. (1995) Disparate responses to oxidative stress in saprophytic and pathogenic mycobacteria. Proc Natl Acad Sci USA 92: 66256629.
  • Sherman, D.R., Mdluli, K., Hickey, M.J., Arain, T.M., Morris, S.L., Barry, C.E., 3rd & Stover, C.K. (1996) Compensatory ahpC gene expression in isoniazid-resistant Mycobacterium tuberculosis. Science 272: 16411643.
  • Siddiqi, S.H., Hawkins, J.E. & Laszlo, A. (1985) Interlaboratory drug susceptibility testing of Mycobacterium tuberculosis by a radiometric procedure and two conventional methods. J Clin Microbiol 22: 919923.
  • Slayden, R.A. & Barry, C.E., 3rd (2000) The genetics and biochemistry of isoniazid resistance in Mycobacterium tuberculosis. Microbes Infect 6: 111.
  • Slayden, R.A., Lee, R.E., Armour, J.W., Cooper, A.M., Orme, I.M., Brennan, P.J. & Besra, G.S. (1996) Antimycobacterial action of thiolactomycin: an inhibitor of fatty acid and mycolic acid synthesis. Antimicrob Agents Chemother 40: 28132819.
  • Sreevatsan, S., Pan, X., Stockbauer, K.E., Connell, N.D., Kreiswirth, B.N., Whittam, T.S. & Musser, J.M. (1997) Restricted structural gene polymorphism in the Mycobacterium tuberculosis complex indicates evolutionarily recent global dissemination. Proc Natl Acad Sci USA 94: 98699874.
  • Stewart, M.J., Parikh, S., Xiao, G., Tonge, P.J. & Kisker, C. (1999) Structural basis and mechanism of enoyl reductase inhibition by triclosan. J Mol Biol 290: 859865.
  • Subrahmanyam, S. & Cronan, J.E., Jr (1998) Overproduction of a functional fatty acid biosynthetic enzyme blocks fatty acid synthesis in Escherichia coli. J Bacteriol 180: 45964602.
  • Takayama, K., Schnoes, H.K., Armstrong, E.L. & Boyle, R.W. (1975) Site of inhibitory action of isoniazid in the synthesis of mycolic acids in Mycobacterium tuberculosis. J Lipid Res 16: 308317.
  • Telenti, A., Honore, N., Bernasconi, C., March, J., Ortega, A. & Heym, B., et al. (1997) Genotypic assessment of isoniazid and rifampin resistance in Mycobacterium tuberculosis: a blind study at reference laboratory level. J Clin Microbiol 35: 719723.
  • Wallace, R.J., Jr, Nash, D.R., Steele, L.C. & Steingrube, V. (1986) Susceptibility testing of slowly growing mycobacteria by a microdilution MIC method with 7H9 broth. J Clin Microbiol 24: 976981.
  • Ward, W.H., Holdgate, G.A., Rowsell, S., McLean, E.G., Pauptit, R.A. & Clayton, E., et al. (1999) Kinetic and structural characteristics of the inhibition of enoyl (acyl carrier protein) reductase by triclosan. Biochemistry 38: 1251412525.
  • Wilming, M. & Johnsson, K. (1999) Spontaneous formation of the bioactive form of the tuberculosis drug isoniazid. Angew Chem Int Ed 38: 25882590.
  • Wilson, M., DeRisi, J., Kristensen, H.-K., Imboden, P., Rane, S., Brown, P.O. & Schoolnik, G.K. (1999) Exploring drug-induced alterations in gene expression in Mycobacterium tuberculosis by microarray hybridization. Proc Natl Acad Sci USA 96: 1283312838.
  • Zhang, Y., Heym, B., Allen, B., Young, D. & Cole, S. (1992) The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 358: 591593.